A股異動丨雪萊特(002076.SZ)漲停 紫外殺菌燈獲多項專利並已入駐火神山醫院
格隆匯2月7日丨雪萊特(002076.SZ)今日高開封板,目前錄得兩連板。現報2.44元,暫成交6539萬元,最新總市值18.89億元。本次新型冠狀病毒肺炎疫情之下,雪萊特積極出力。1月27日,公司捐贈的第一批3269台紫外燈具順利抵達武漢火神山醫院工地,助力醫院消毒工作。公司研發生產紫外線殺菌燈已有近20年,參與起草了《紫外線殺菌燈》國家標準,在紫外線殺菌燈領域擁有多項發明、實用新型及外觀設計專利。值得注意的是,日前柴國生被動減持期過半,累計減持573.7萬股。另外,公司預計2019年同比減虧5.27%-46.04%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.